Literature DB >> 32206598

Cardiovascular risk and mortality in patients with active and treated hypercortisolism.

Dingfeng Li1, Omar M El Kawkgi1, Andres F Henriquez1, Irina Bancos1.   

Abstract

Patients with hypercortisolism demonstrate high cardiovascular morbidity and mortality, especially if diagnosis is delayed. Hypercortisolism-induced cardiovascular and metabolic comorbidities include hypertension, impaired glucose metabolism, dyslipidemia, and obesity. High prevalence of cardiovascular risk factors leads to increased rate of cardiovascular events and mortality. This risk is reduced, albeit not reversed even after successful treatment of hypercortisolism. In this review we will describe prevalence and mechanisms of cardiovascular comorbidities in patients with hypercortisolism. In addition, we will summarize the effect of therapy on cardiovascular risk factors, events, as well as mortality. 2020 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Cushing syndrome (CS); cardiovascular events; dyslipidemia; glucose metabolism; hypertension; mild autonomous cortisol secretion (MACS)

Year:  2020        PMID: 32206598      PMCID: PMC7082278          DOI: 10.21037/gs.2019.11.03

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  100 in total

Review 1.  Subclinical hypercortisolism: a state, a syndrome, or a disease?

Authors:  Guido Di Dalmazi; Renato Pasquali; Felix Beuschlein; Martin Reincke
Journal:  Eur J Endocrinol       Date:  2015-08-17       Impact factor: 6.664

2.  Mortality in Cushing's syndrome: systematic analysis of a large series with prolonged follow-up.

Authors:  G Ntali; A Asimakopoulou; T Siamatras; J Komninos; D Vassiliadi; M Tzanela; S Tsagarakis; A B Grossman; J A H Wass; N Karavitaki
Journal:  Eur J Endocrinol       Date:  2013-10-08       Impact factor: 6.664

3.  Ketoconazole therapy: an efficacious alternative to achieve eucortisolism in patients with Cushing's syndrome.

Authors:  Daniel Moncet; Daniel J Morando; Fabian Pitoia; Silvia B Katz; Maria A Rossi; Oscar D Bruno
Journal:  Medicina (B Aires)       Date:  2007       Impact factor: 0.653

Review 4.  Mortality in Cushing's syndrome: a systematic review and meta-analysis.

Authors:  D Graversen; P Vestergaard; K Stochholm; C H Gravholt; J O L Jørgensen
Journal:  Eur J Intern Med       Date:  2011-11-15       Impact factor: 4.487

5.  Exaggerated blood pressure response to angiotensin II in patients with Cushing's syndrome due to adrenocortical adenoma.

Authors:  G Yasuda; H Shionoiri; S Umemura; I Takasaki; M Ishii
Journal:  Eur J Endocrinol       Date:  1994-12       Impact factor: 6.664

6.  Lipomodulin: a possible mediator of the action of glucocorticoids.

Authors:  F Hirata
Journal:  Adv Prostaglandin Thromboxane Leukot Res       Date:  1983

7.  New-Onset Resistant Hypertension in a Newly Diagnosed Prostate Cancer Patient.

Authors:  Nattawat Klomjit; Daniel J Rowan; Andrea G Kattah; Irina Bancos; Sandra J Taler
Journal:  Am J Hypertens       Date:  2019-11-15       Impact factor: 2.689

8.  Metyrapone in long-term management of Cushing's disease.

Authors:  W J Jeffcoate; L H Rees; S Tomlin; A E Jones; C R Edwards; G M Besser
Journal:  Br Med J       Date:  1977-07-23

9.  LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study.

Authors:  Xavier Bertagna; Rosario Pivonello; Maria Fleseriu; Yiming Zhang; Paul Robinson; Ann Taylor; Catherine E Watson; Mario Maldonado; Amir H Hamrahian; Marco Boscaro; Beverly M K Biller
Journal:  J Clin Endocrinol Metab       Date:  2013-12-11       Impact factor: 5.958

10.  Coronary artery disease detected by multislice computed tomography in patients after long-term cure of Cushing's syndrome.

Authors:  María-José Barahona; Eugenia Resmini; David Viladés; Guillem Pons-Lladó; Rubén Leta; Teresa Puig; Susan M Webb
Journal:  J Clin Endocrinol Metab       Date:  2013-02-07       Impact factor: 5.958

View more
  7 in total

1.  Cushing syndrome secondary to a mediastinal carcinoid tumor: a case report.

Authors:  Reza Ershadi; Matin Vahedi; Behnaz Jahanbin; Javad Sarbazzadeh; Shahab Rafieian
Journal:  Int Cancer Conf J       Date:  2022-02-23

2.  Abnormal body composition in patients with adrenal adenomas.

Authors:  Danae A Delivanis; Maria D Hurtado Andrade; Tiffany Cortes; Shobana Athimulam; Aakanksha Khanna; Elizabeth Atkinson; Travis McKenzie; Naoki Takahashi; Michael R Moynagh; Irina Bancos
Journal:  Eur J Endocrinol       Date:  2021-10-08       Impact factor: 6.558

3.  Long-term efficacy and safety of osilodrostat in Cushing's disease: final results from a Phase II study with an optional extension phase (LINC 2).

Authors:  Maria Fleseriu; Beverly M K Biller; Jérôme Bertherat; Jacques Young; Betul Hatipoglu; Giorgio Arnaldi; Paul O'Connell; Miguel Izquierdo; Alberto M Pedroncelli; Rosario Pivonello
Journal:  Pituitary       Date:  2022-10-11       Impact factor: 3.599

4.  The Effect of Curative Treatment on Hyperglycemia in Patients With Cushing Syndrome.

Authors:  Justine Herndon; Ravinder Jeet Kaur; Mark Romportl; Emily Smith; Amy Koenigs; Brenda Partlow; Leonardo Arteaga; Irina Bancos
Journal:  J Endocr Soc       Date:  2021-12-02

5.  Preanalytical Pitfalls in Untargeted Plasma Nuclear Magnetic Resonance Metabolomics of Endocrine Hypertension.

Authors:  Nikolaos G Bliziotis; Leo A J Kluijtmans; Gerjen H Tinnevelt; Parminder Reel; Smarti Reel; Katharina Langton; Mercedes Robledo; Christina Pamporaki; Alessio Pecori; Josie Van Kralingen; Martina Tetti; Udo F H Engelke; Zoran Erlic; Jasper Engel; Timo Deutschbein; Svenja Nölting; Aleksander Prejbisz; Susan Richter; Jerzy Adamski; Andrzej Januszewicz; Filippo Ceccato; Carla Scaroni; Michael C Dennedy; Tracy A Williams; Livia Lenzini; Anne-Paule Gimenez-Roqueplo; Eleanor Davies; Martin Fassnacht; Hanna Remde; Graeme Eisenhofer; Felix Beuschlein; Matthias Kroiss; Emily Jefferson; Maria-Christina Zennaro; Ron A Wevers; Jeroen J Jansen; Jaap Deinum; Henri J L M Timmers
Journal:  Metabolites       Date:  2022-07-24

Review 6.  Approach to the Patient With Adrenal Incidentaloma.

Authors:  Irina Bancos; Alessandro Prete
Journal:  J Clin Endocrinol Metab       Date:  2021-10-21       Impact factor: 6.134

Review 7.  Pathophysiology of Mild Hypercortisolism: From the Bench to the Bedside.

Authors:  Vittoria Favero; Arianna Cremaschi; Chiara Parazzoli; Alberto Falchetti; Agostino Gaudio; Luigi Gennari; Alfredo Scillitani; Fabio Vescini; Valentina Morelli; Carmen Aresta; Iacopo Chiodini
Journal:  Int J Mol Sci       Date:  2022-01-08       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.